Personalized medicine in multiple sclerosis: hope or reality?

Personalized treatment is highly desirable in multiple sclerosis because it is an immensely heterogeneous disease. This heterogeneity is seen in both the disease course and the treatment responses. Currently, a combination of clinical features and imaging parameters in magnetic resonance imaging is...

Descripción completa

Detalles Bibliográficos
Autor principal: Derfuss, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523020/
https://www.ncbi.nlm.nih.gov/pubmed/23035757
http://dx.doi.org/10.1186/1741-7015-10-116
_version_ 1782253159169654784
author Derfuss, Tobias
author_facet Derfuss, Tobias
author_sort Derfuss, Tobias
collection PubMed
description Personalized treatment is highly desirable in multiple sclerosis because it is an immensely heterogeneous disease. This heterogeneity is seen in both the disease course and the treatment responses. Currently, a combination of clinical features and imaging parameters in magnetic resonance imaging is used to classify active and non-active patients and treatment responders and non-responders. Although this classification works on a group level, individual patients often behave differently from the group. Therefore additional biomarkers are needed to provide better indicators for prognosis and treatment response. Basic and clinical research have discovered different promising targets. It is now essential to verify the utility and accuracy of these markers in large, prospectively sampled patient cohorts.
format Online
Article
Text
id pubmed-3523020
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35230202012-12-16 Personalized medicine in multiple sclerosis: hope or reality? Derfuss, Tobias BMC Med Minireview Personalized treatment is highly desirable in multiple sclerosis because it is an immensely heterogeneous disease. This heterogeneity is seen in both the disease course and the treatment responses. Currently, a combination of clinical features and imaging parameters in magnetic resonance imaging is used to classify active and non-active patients and treatment responders and non-responders. Although this classification works on a group level, individual patients often behave differently from the group. Therefore additional biomarkers are needed to provide better indicators for prognosis and treatment response. Basic and clinical research have discovered different promising targets. It is now essential to verify the utility and accuracy of these markers in large, prospectively sampled patient cohorts. BioMed Central 2012-10-04 /pmc/articles/PMC3523020/ /pubmed/23035757 http://dx.doi.org/10.1186/1741-7015-10-116 Text en Copyright ©2012 Derfuss; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Minireview
Derfuss, Tobias
Personalized medicine in multiple sclerosis: hope or reality?
title Personalized medicine in multiple sclerosis: hope or reality?
title_full Personalized medicine in multiple sclerosis: hope or reality?
title_fullStr Personalized medicine in multiple sclerosis: hope or reality?
title_full_unstemmed Personalized medicine in multiple sclerosis: hope or reality?
title_short Personalized medicine in multiple sclerosis: hope or reality?
title_sort personalized medicine in multiple sclerosis: hope or reality?
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523020/
https://www.ncbi.nlm.nih.gov/pubmed/23035757
http://dx.doi.org/10.1186/1741-7015-10-116
work_keys_str_mv AT derfusstobias personalizedmedicineinmultiplesclerosishopeorreality